Coeptis Therapeutics, Inc.
COEP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $75 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $1,039 | $1,001 | $1,001 | $0 |
| Gross Profit | -$1,039 | -$1,001 | -$1,001 | $75 |
| % Margin | – | – | – | 100% |
| R&D Expenses | $2,332 | $6,668 | $21 | $0 |
| G&A Expenses | $0 | $0 | $0 | $14,118 |
| SG&A Expenses | $6,684 | $13,822 | $33,174 | $14,121 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $3 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $9,016 | $20,490 | $33,195 | $14,121 |
| Operating Income | -$10,054 | -$21,491 | -$34,196 | -$14,046 |
| % Margin | – | – | – | -18,727.9% |
| Other Income/Exp. Net | -$823 | $225 | -$3,378 | $597 |
| Pre-Tax Income | -$10,877 | -$21,267 | -$37,574 | -$13,449 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$10,877 | -$21,267 | -$37,574 | -$13,449 |
| % Margin | – | – | – | -17,932.4% |
| EPS | -5.65 | -0.83 | -2.87 | -13.16 |
| % Growth | -580.7% | 71.1% | 78.2% | – |
| EPS Diluted | -5.65 | -0.83 | -2.87 | -13.16 |
| Weighted Avg Shares Out | 1,925 | 25,690 | 14,296 | 1,022 |
| Weighted Avg Shares Out Dil | 1,925 | 25,690 | 14,296 | 1,022 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $396 | $108 | $218 | $187 |
| Depreciation & Amortization | $1,039 | $1,001 | $1,001 | $447 |
| EBITDA | -$9,443 | -$20,158 | -$36,354 | -$12,815 |
| % Margin | – | – | – | -17,086.3% |